FDAnews Drug Daily Bulletin
Pharmaceuticals / Regulatory Affairs

Congressional Report Suggests Ways to Cut Insulin Prices

Nov. 12, 2018
A A

The Congressional Diabetes Caucus called on policymakers to take steps to bring down insulin prices, including requiring insulin manufacturers and pharmacy benefit managers to disclose rebate details.

The caucus, a bipartisan group of nearly 300 House members, made 11 policy recommendations in a report released by co-chairs Reps. Diana De Gette (D-Colo.) and Tom Reed (R-N.Y.). They include measures encouraging the use of value-based contracts between PBMs and insulin manufacturers, such as directing the Centers for Medicare and Medicaid Services to pilot outcomes-based pricing arrangements in Medicare.

Lawmakers should consider requiring insulin manufacturers, PBMs and federal insurers’ drug plans to disclose their use of rebates, the caucus said.

View today's stories